Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany
出版年份 2015 全文链接
标题
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany
作者
关键词
Overall Survival, Epidermal Growth Factor Receptor, Erlotinib, Pemetrexed, Epidermal Growth Factor Receptor Mutation
出版物
PHARMACOECONOMICS
Volume 33, Issue 11, Pages 1215-1228
出版商
Springer Nature
发表日期
2015-06-16
DOI
10.1007/s40273-015-0305-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Thresholds for the cost–effectiveness of interventions: alternative approaches
- (2015) Elliot Marseille et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review
- (2014) T Brown et al. HEALTH TECHNOLOGY ASSESSMENT
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Afatinib in the treatment of EGFR mutation-positive NSCLC – A network meta-analysis
- (2014) Sanjay Popat et al. LUNG CANCER
- Is Individualized Medicine More Cost-Effective? A Systematic Review
- (2014) Maximilian H. M. Hatz et al. PHARMACOECONOMICS
- Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
- (2014) Wenhua Liang et al. PLoS One
- A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
- (2014) Ansgar Lange et al. BMC Pulmonary Medicine
- Population-Based Risk for Complications After Transthoracic Needle Lung Biopsy of a Pulmonary Nodule: An Analysis of Discharge Records
- (2013) Renda Soylemez Wiener et al. ANNALS OF INTERNAL MEDICINE
- Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis
- (2013) Jun Zhu et al. BMC CANCER
- EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice
- (2013) S Gahr et al. BRITISH JOURNAL OF CANCER
- The prevalence of weight loss during (chemo)radiotherapy treatment for lung cancer and associated patient- and treatment-related factors
- (2013) Nicole Kiss et al. CLINICAL NUTRITION
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies
- (2013) Xiaoqing Liu et al. JOURNAL OF CLINICAL PATHOLOGY
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
- (2013) Neal I. Lindeman et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Economic burden of cancer across the European Union: a population-based cost analysis
- (2013) Ramon Luengo-Fernandez et al. LANCET ONCOLOGY
- Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany
- (2013) Shrividya Iyer et al. LUNG CANCER
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data
- (2013) Nicholas R. Latimer MEDICAL DECISION MAKING
- A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events
- (2013) Fatiha H. Shabaruddin et al. PHARMACOECONOMICS
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME)
- (2012) Philipp A. Schnabel et al. LUNG CANCER
- Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies
- (2012) Arne Warth et al. VIRCHOWS ARCHIV
- Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung
- (2012) Elizabeth A. Handorf et al. Journal of Oncology Practice
- Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
- (2011) Gilberto de Lima Lopes et al. CANCER
- 9144 POSTER EGFR Mutation Testing and First Line Treatment of Patients With Advanced NSCLC and Positive EGFR Mutation Status – Results From a German Registry
- (2011) W. Eberhardt et al. EUROPEAN JOURNAL OF CANCER
- Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
- (2011) I. Borget et al. EUROPEAN RESPIRATORY JOURNAL
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
- (2010) Yumi Asukai et al. BMC CANCER
- The efficiency frontier approach to economic evaluation of health-care interventions
- (2010) J. Jaime Caro et al. HEALTH ECONOMICS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health state utilities for non small cell lung cancer
- (2008) Beenish Nafees et al. Health and Quality of Life Outcomes
- The NICE Cost-Effectiveness Threshold
- (2008) Christopher McCabe et al. PHARMACOECONOMICS
- Health State Utility Scores for Cancer-Related Anemia through Societal and Patient Valuations
- (2008) Andrew Lloyd et al. VALUE IN HEALTH
- The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer
- (2008) Josh J. Carlson et al. VALUE IN HEALTH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation